ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review. - Wikidata - awgldk - TriplyDB

ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.

ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.

http://www.wikidata.org/entity/Q35106265

about

Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells Primary anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma of the breast in a male patient.Research progresses in the pathogenesis of anaplastic large cell lymphoma.Occurrence of anaplastic large cell lymphoma following IgG4-related autoimmune pancreatitis and cholecystitis and diffuse large B-cell lymphoma A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.Extrinsic apoptotic pathways: a new potential "target" for more sufficient therapy in a case of cutaneous anaplastic large cd30+ alk-T-cell lymphoma Role of molecular studies in the classification of lymphoma.Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations.Inhibition of Granzyme B by PI-9 protects prostate cancer cells from apoptosis.Simultaneous cytomorphological and multiparameter flow cytometric analysis of ALK-positive anaplastic large cell lymphoma in children.Anaplastic lymphoma kinase negative anaplastic large cell lymphoma of hard palate as first clinical manifestation of acquired immune deficiency syndrome Predicting the outcome in non-Hodgkin lymphoma with molecular markers.Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity.CD30-Positive Anaplastic Lymphoma Kinase-Negative Systemic Anaplastic Large-Cell Lymphoma in a 9-Year-Old Boy.Gingival Anaplastic Large-Cell Lymphoma Mimicking Hyperplastic Benignancy as the First Clinical Manifestation of AIDS: A Case Report and Review of the Literature.MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient.Human Immunodeficiency Virus-associated anaplastic large cell lymphoma.Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.Variable presentation of anaplastic large-cell lymphoma in patients with breast implants.Myxoid variant of primary cutaneous anaplastic large cell lymphoma: First 2 cases.Skin involvement as the first manifestation of breast implant-associated anaplastic large cell lymphoma.Anaplastic large cell lymphoma: an unusual presentation in a 7-year-old girl.Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas.Primary cutaneous anaplastic large cell lymphoma.Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma

P2860

Q24293644-B041F80C-5214-49EE-B350-AE1D003DC0C8 Q24652793-F5BAC1B7-1ADC-4C44-AA20-31AC6EA36CB5 Q24656281-CBEAF6AF-4264-4AC0-8571-616EF9248F4F Q30455790-14580446-387E-4FDE-8924-C8748F8C8219 Q33579708-323CB04F-7F72-4D66-8FDF-07AA71542C24 Q34384895-0B53692A-6E62-4AEC-B745-0D078D1678D3 Q34438994-AFFB5647-ABE1-45D9-83AA-35C9136A08DD Q34941890-5B960D93-97F6-4B86-B20D-076F75F502E1 Q35623363-590B868A-7B00-4CEC-B09D-8070D73C4EC3 Q35697053-C676D91E-B6AD-49A1-B574-863AE49BFB77 Q36106303-00FFD3C7-434D-4316-9E44-FA62ACBB9ECB Q36611784-AFD1F537-BA9F-49C1-8387-5ADADDD5FF83 Q36687570-58BD9D2F-668E-4351-A212-0DADAA0CDC7B Q36780164-C708D392-32A4-44DF-94B9-EB9BEA0E60DF Q36849529-29C00D4F-FE66-4256-B6E9-B5A2870117B1 Q36946025-C10C90EF-C0F4-4860-A5B1-5423AC93F046 Q36969196-592D4243-F2B7-44DB-80A7-C82A593B7691 Q37186470-BBB12590-5878-4676-8507-A4E9AE2B2084 Q37412590-A882B035-A2D5-449A-BC53-E75C5AE6B831 Q37689183-EEBBFFD4-61E1-436E-98F0-CF32FB6E3203 Q37814419-7DF71A24-0986-44CD-A42F-0D025D0737F9 Q37848818-DDA177B0-8551-4B39-BD9A-618486D5A3C0 Q37863688-FC55B243-C171-4F00-941C-9625D6729C4E Q39746344-F64B2767-D548-44AD-86AA-C9B2A45ADC86 Q39816246-FDF074F2-A312-4F4A-AFF0-9EEC5B127912 Q41366930-40526C07-294D-4C45-8BF4-D31522F0C87A Q45252488-B9CAD8D6-2989-45DA-B84D-B243520F9ADF Q53153612-DECFDABF-1896-4F0E-AE98-0774C90D4B8D Q53215323-7A748134-1E8B-4BEC-B5C9-50DDC85719B0 Q54546572-B4FE91BA-50E5-4DBC-BC50-69DDC91D5F84 Q54663256-0F42F0EF-ED3D-4CC2-9410-01838AB97C93 Q57918686-EBCA91CA-D800-45E2-8C9E-87F8182C9169

P2860

ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.

http://www.wikidata.org/entity/Q35106265

description

2003 nî lūn-bûn

@nan

2003 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

ALK-negative systemic anaplast ...... prognostic aspects--a review.

@ast

ALK-negative systemic anaplast ...... prognostic aspects--a review.

@en

type

label

ALK-negative systemic anaplast ...... prognostic aspects--a review.

@ast

ALK-negative systemic anaplast ...... prognostic aspects--a review.

@en

prefLabel

ALK-negative systemic anaplast ...... prognostic aspects--a review.

@ast

ALK-negative systemic anaplast ...... prognostic aspects--a review.

@en

P1433

Q35106265-2F811310-FCBB-4B3E-9268-8DC3A43D649C

P1476

Q35106265-77941CFA-09CD-43CE-9DDB-4B18F3D24D5C

P2093

Q35106265-01CBCFD3-6A62-48AE-81CA-8EAF58DA3EB7

Q35106265-3629016C-6D7E-4397-8482-4250C9E98A4E

Q35106265-606D45C9-D127-4006-BE0D-AAC015EABE9E

Q35106265-6970C566-0239-4EA3-B940-B55DB956C8E4

P2860

Q35106265-22AD3925-3929-4EF3-AF39-4A29D89EC399

Q35106265-43F5D851-119D-47E5-AC48-E34B4FACBFB1

Q35106265-43FE3EF0-64F5-4215-8EC8-135DAFF1A54B

Q35106265-60FA8E40-040B-49C4-8C36-1C2E754BC861

Q35106265-69B22F4A-FEA5-4408-9862-5115BC877F39

Q35106265-85AE846F-F41D-41D2-ABD4-630C9B23E3D6

Q35106265-A50E741A-467F-4DF8-8CDB-22A4334016D4

Q35106265-B77FDBE2-C578-4E84-AD6F-277814C2C73C

Q35106265-CEB5DD9E-A587-43D6-BB87-012024C4271C

Q35106265-D99C5FAC-8CC7-4DD2-8323-EA4DEBA80A91

P304

Q35106265-0E535DDE-6D1B-42D8-97E0-D58FCCF842E9

P31

Q35106265-7813F4B4-892B-49E7-B76C-29DD61CC451D

P356

Q35106265-95DB360F-BB14-4024-BA50-3A41434C394E

P433

Q35106265-83CC4E9B-0298-498E-A493-3BD9B3321831

P478

Q35106265-313A9276-D173-4321-B77B-32DE6D5435DA

P577

Q35106265-E252D3D0-D1EF-49E5-9233-A11BF7268DE2

P698

Q35106265-1F4FABAE-D899-401C-8E38-BCB56DF3123A

P356

P1433

The Journal of Pathology

P1476

ALK-negative systemic anaplast ...... prognostic aspects--a review.

@en

P2093

Chris J L M Meijer

http://www.w3.org/2001/XMLSchema#string

Gert J Ossenkoppele

http://www.w3.org/2001/XMLSchema#string

Joost J Oudejans

http://www.w3.org/2001/XMLSchema#string

Rosita L ten Berge

http://www.w3.org/2001/XMLSchema#string

P2860

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis

Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity

Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway

Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria

Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage

ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.

ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum.

Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma.

CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases.

P304

4-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PATH.1331

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

200

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12692835

http://www.w3.org/2001/XMLSchema#string